Northwest Biotherapeutics: A Critique Of Adam Feuerstein Of TheStreet's Recent Analysis [View article]
Indiansfan407, it wasn't our intention to inflame, but I do respect your overriding point.
The editor made a judgment call during the publishing process. We saw the author's comment, contacted him with a proposed change, which he approved, and then acknowledged the change being made per his request here, so all information was public. It is always our intention to partner with our contributors to reflect the sentiments of their article, and we will learn from this and apply it going forward.
Can They Spare A Penny A Click For International Coverage? [View instapost]
Hello all,
Thanks for the continuous commentary and input here. I wanted to let you know I touched based with Jon, and as you've all likely seen, he has written two articles on his area of expertise. I highly recommend you check them out.
Two points of clarification. His articles do qualify for our premium submission, and have. There was a miscommunication that created confusion on both sides. Second, his recent articles show how we need international articles to be done. We remain focused on US securities, and will. However, one can, as Jon has, write about portfolio strategies that provide international exposure through domestic securities. This can be complemented with thoughts on how to access these markets directly, just like fundamental analysis can be complemented with technicals.
I hope this helps clarify for everyone, and I look forward to continuing to work with Jon and share his ideas with SA readers.
Can They Spare A Penny A Click For International Coverage? [View instapost]
Thanks everyone for the great conversation on this important issue. Jon is a highly valued contributor and we certainly don't want to lose his solid investing insights. The comments above make a compelling argument, and give us lots of food for thought. Jon, thanks for raising it, and for the great stuff you've written on Mongolia and other places. There are a multitude of reasons for our current practice, but I do intend to ponder this and see if there's a middle ground we can reach. I will contact you directly with questions on this.
We wanted to bring the Editor's Note that has been added above to your attention, as we feel readers and commenters should be aware: It was disclosed after publication of this article that the author is seeking public relations business from AMPE. He also disclosed previously that the company paid for his transportation to their facility.
A New Look At Galena's NeuVax While Lowering Analyst's Raised Red Flags [View article]
This was removed unintentionally, please find Adam's initial comment below: ""Rich Steffens acknowledges that he's no expert in biostatistics or onocology drug trials. Unfortunately, Seeking Alpha didn't bother to fact check this column, which is rife with errors. Contrary to Steffens' claims, recurrence rate and disease-free survival are the inverse of each other. GALE has used both measures interchangeably to describe data from the NeuVax study. My reporting on the discrepancy between what GALE reported last December in the SABCS poster and what was reported this May in the ASCO abstract stands and is valid. My analysis does not have a "fatal flaw" as Steffens claims. His understanding of the data is mistaken and his characterization of my work should be corrected and/or retracted."
3 Stocks That Are Headed For A Correction [View article]
Please note that DDMG contacted us and the author of this piece to report that the lockup period does not expire until June 4. This is due to a clause in the agreement related to the company's earnings report. The article has been updated with this information.
The Why Behind The How: The Quality Of Comments On Seeking Alpha Articles [View instapost]
Hey all,
Truly love the commentary here. Rocco and I discussed this via email and agree that while it is great stuff, it is instablog, not an article. (We also discussed hockey, but that's more painful for him than ill-conceived comments, so let's not discuss that here.)
The Why Behind The How: The Quality Of Comments On Seeking Alpha Articles [View instapost]
Rocco, I'm curious what efforts were made to mitigate that in talk radio. While a completely different medium, there might be some ideas that we can apply to be as proactive as possible.
Northwest Biotherapeutics: A Critique Of Adam Feuerstein Of TheStreet's Recent Analysis [View article]
The editor made a judgment call during the publishing process. We saw the author's comment, contacted him with a proposed change, which he approved, and then acknowledged the change being made per his request here, so all information was public. It is always our intention to partner with our contributors to reflect the sentiments of their article, and we will learn from this and apply it going forward.
Northwest Biotherapeutics: A Critique Of Adam Feuerstein Of TheStreet's Recent Analysis [View article]
Thanks,
GBM
5 Dividend Stocks For 2013 [View article]
Can They Spare A Penny A Click For International Coverage? [View instapost]
Thanks for the continuous commentary and input here. I wanted to let you know I touched based with Jon, and as you've all likely seen, he has written two articles on his area of expertise. I highly recommend you check them out.
Two points of clarification. His articles do qualify for our premium submission, and have. There was a miscommunication that created confusion on both sides. Second, his recent articles show how we need international articles to be done. We remain focused on US securities, and will. However, one can, as Jon has, write about portfolio strategies that provide international exposure through domestic securities. This can be complemented with thoughts on how to access these markets directly, just like fundamental analysis can be complemented with technicals.
I hope this helps clarify for everyone, and I look forward to continuing to work with Jon and share his ideas with SA readers.
Can They Spare A Penny A Click For International Coverage? [View instapost]
Can They Spare A Penny A Click For International Coverage? [View instapost]
IPO Market Update: Calm Into High Gear [View article]
The Economics Of Syngas-To-Liquids, Part II [View article]
Traders Eye Ampio [View article]
Exelon: Another Way To Play Rising Natural Gas Prices [View article]
SodaStream Consumables Tell You All You Need To Know [View article]
A New Look At Galena's NeuVax While Lowering Analyst's Raised Red Flags [View article]
3 Stocks That Are Headed For A Correction [View article]
The Why Behind The How: The Quality Of Comments On Seeking Alpha Articles [View instapost]
Truly love the commentary here. Rocco and I discussed this via email and agree that while it is great stuff, it is instablog, not an article. (We also discussed hockey, but that's more painful for him than ill-conceived comments, so let's not discuss that here.)
The Why Behind The How: The Quality Of Comments On Seeking Alpha Articles [View instapost]
Thanks,
GBM